Meihua Faces Nasdaq Delisting After Failing Key Compliance Rules
Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice
Yangzhou, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Meihua International Medical Technologies Co., Ltd. ('Meihua' or the
2025-12-05T21:05:00+00:00
strategy, market, update, compliance, press release, stock, finance, business, stock-market
Meihua International Medical Technologies Co., Ltd. (MHUA) has been notified of its delisting from Nasdaq. The decision, announced on December 2, 2025, follows the company’s failure to meet key listing requirements. In response, Meihua has requested an appeal before a hearing panel.
The delisting stems from two main violations. First, the company did not comply with Nasdaq Listing Rule 5550(a)(2) for over 30 consecutive business days. Second, it failed to maintain at least 500,000 publicly held shares, a mandatory threshold for continued listing on the Nasdaq today.
On November 8, 2025, shareholders approved a reverse stock split and a dual-class stock structure. This change took effect on November 24, 2025, drastically reducing outstanding common shares from roughly 56 million to about 0.56 million. VStock Transfer, LLC acted as the exchange agent for the transaction.
Meihua, a manufacturer of disposable medical devices, has operated for over 30 years. Its products include Class I, II, and III medical supplies, with over 1,000 types sold domestically and more than 120 exported to 30 countries. The company serves hospitals, pharmacies, and medical institutions globally.
Trading of Meihua’s ordinary shares will be suspended from December 9, 2025, unless the appeal alters the decision.
The delisting process moves forward unless the hearing panel overturns Nasdaq’s decision. Meihua’s shares will halt trading next week, marking a significant shift for the long-standing medical device supplier. The outcome of the appeal will determine whether the company remains on the Nasdaq composite.
